Our research concentrates on advancing immunotherapies by identifying novel targets, enhancing existing ones, and identifying biomarkers for immunotherapy responses. Using proteomics and bioinformatics, we explore new targets for leukemia and lymphoma immunotherapies. We validate identified surface proteins using the OncoProbe platform. In collaboration with Oslo University Hospital, we develop novel CAR-T therapies for newly identified targets. We also investigate surface protein expression regulation, aiming to boost chemo-immunotherapy effectiveness. Additionally, we study biomarkers for CAR-T therapy response, focusing on protease activation in CAR-T cells. Collaborating with Dr Marcin Poręba from Wrocław University of Science and Technology, we research new chemical probes for assessing CAR-T cell activity in patients' blood.